Data collection for the sake of data collection 177 8♦ 79. Parente P, Ng S, Parnis F, Guminski A, Gurney H. Cabazitaxel in patients with metastatic castration-resistant prostate cancer: safety and quality of life data from the Australian early access program. Asia Pac J Clin Oncol. 2017;13(6):391-399. 80. Treatments and vaccines for COVID-19 | European Medicines Agency. Accessed January 8, 2023. https://www.ema.europa.eu/en/humanregulatory/overview/public-health-threats/ coronavirus-disease-covid-19/treatmentsvaccines-covid-19 81. Know Your Treatment Options for COVID-19 | FDA. Accessed January 8, 2023. https://www.fda. gov/consumers/consumer-updates/know-yourtreatment-options-covid-19 82. Scepura B, Chan M, Kim T, Boehmer J, Goldberg KB, Pazdur R. Oncology Expanded Access and FDA’s Project Facilitate. The oncologist. 2021;26(10):e1880-e1882. doi:10.1002/ onco.13910 83. Kalil AC. Treating COVID-19 - Off-Label Drug Use, Compassionate Use, and Randomized Clinical Trials during Pandemics. JAMA - J Am Med Assoc. Published online 2020. doi:10.1001/ jama.2020.4742 84. BASG. Information on Named Patient Use (Heilversuch) in Austria - Definition and Framework.; 2015. 85. Bakker E, Plueschke K, Jonker CJ, Kurz X, Starokozhko V, Mol PGM. Contribution of RealWorld Evidence in European Medicines Agency’s Regulatory Decision Making. Clin Pharmacol Ther. 2023;113(1). doi:10.1002/cpt.2766 86. Purpura CA, Garry EM, Honig N, Case A, Rassen JA. The Role of Real-World Evidence in FDAApproved New Drug and Biologics License Applications. Clin Pharmacol Ther. 2022;111(1). doi:10.1002/cpt.2474 87. Polak TB, Fernandez Lynch H. The Ethics of Expanded Access Research. JAMA. 2023;329(13):1057. doi:10.1001/ jama.2023.2204 88. Budhai A, Wu AA, Hall L, et al. How did we rapidly implement a convalescent plasma program? Transfusion (Paris). 2020;60(7):13481355. doi:10.1111/trf.15910 89. Joyner MJ, Carter RE, Senefeld JW, et al. Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19. N Engl J Med. 2021;384(11):1015-1027. doi:10.1056/ NEJMoa2031893 90. Kunze KL, Johnson PW, van Helmond N, et al. Mortality in individuals treated with COVID-19 convalescent plasma varies with the geographic provenance of donors. Nat Commun. 2021;12(1):4864. 91. Liu M, Chen Z, Dai MY, et al. Lessons learned from early compassionate use of convalescent plasma on critically ill patients with Covid-19. Transfusion (Paris). 2020;60(10):2210-2216. 92. Banerjee R, Prasad V. Are Observational, Real-World Studies Suitable to Make Cancer Treatment Recommendations? JAMA Netw Open. 2020;3(7):e2012119-e2012119. doi:10.1001/ jamanetworkopen.2020.12119
RkJQdWJsaXNoZXIy MTk4NDMw